Oncology Drugs

NorthStar Medical Radioisotopes will showcase its revolutionary cancer-fighting isotopes, Ac-225 and Cu-67, at the prestigious J.P. Morgan conference.

New data reveals a novel therapy shrinks tumors in salivary gland cancer, offering hope where few options exist and validating a new oncology platform.

A new once-monthly, self-injected cholesterol drug gets FDA nod, offering more convenience and setting the stage for a major market push in China.

New data shows Vyriad's VV169 eliminated myeloma in mice without severe toxicity, signaling a potential shift to safer, scalable 'off-the-shelf' CAR T.

A decade-long wait ends as the FDA approves a new 1st-line therapy for HER2+ breast cancer. See how ENHERTU reshapes patient outcomes and market dynamics.

A new drug for a leading cause of blindness missed its primary goal, yet its unique ability to improve vision offers new hope for millions of patients.

Vanda Pharmaceuticals submits its novel GPP therapy, imsidolimab, for FDA review, offering new hope for patients and bolstering its rare disease portfolio.

A positive EU opinion for Sobi's Aspaveli could bring the first-ever targeted treatment for two rare kidney diseases, shaking up a market desperate for innovation.

Genmab's $8 billion acquisition of Merus isn't just a deal; it's a bold strategy to own its destiny and dominate the future of oncology therapeutics.

Health Union's new platform for ATTR amyloidosis isn't just a website. It's a strategic blend of patient support and business innovation. Here's why.

Early results for INT230-6 show 50% fewer severe side effects, raising hopes for a treatment that could eliminate the toxic 'red devil' chemo.

With leadership buying shares and promising trial data for its novel cancer drug, MAIA Biotechnology is sending strong signals to investors. What's next?

Aardvark Therapeutics' pivotal trial for Prader-Willi syndrome goes global, a key step toward commercializing its novel hunger-suppressing drug.

Regulatory filings reveal Balyasny Asset Management's strategic trades in Avadel Pharma, offering a glimpse into the high-stakes bidding war with Alkermes.

Ontario's new FAST program speeds access to cancer drugs like Scemblix, challenging Canada's slow reimbursement system. Is this a new national blueprint?

Promising data for NuCana's NUC-7738 offers hope for tough-to-treat melanoma, but the biotech's financial health presents a critical hurdle.

A new partnership aims to commercialize Arbli™, the first liquid losartan, leveraging a digital platform to solve patient adherence and capture market share.

A novel drug for heart failure shows promising safety and efficacy data, potentially disrupting a multi-billion dollar market and validating a key investor's strategy.

Beyond a simple FDA approval, Amneal's entry into the epinephrine vial market is a calculated move to fix a broken supply chain and drive growth.

A regulatory filing from Balyasny Asset Management reveals intense investor activity as a bidding war for narcolepsy drugmaker Avadel heats up.